XORTX Therapeutics (XRTX) Study Update summary

Program focus and pipeline

• Lead program targets gout, specifically allopurinol-intolerant patients, with a secondary focus on autosomal dominant polycystic kidney disease (ADPKD).

• Preparing to file an Investigational New Drug (IND) application for gout in the next quarter, with NDA submission targeted for the first half of 2026.

• ADPKD program (XRx-008) will resume after revenue from the gout program is established, with registration trials planned and orphan designation targeted.

• The pipeline includes additional candidates such as XRx-101 and XRx-225, supporting long-term growth.

• The company is seeking global or jurisdictional partnerships for commercialization.

Clinical and regulatory progress

• Oxypurinol, the active drug, has a strong safety and efficacy record in over 800 patients, with published data supporting its advancement.

• FDA has requested a small medical study with the commercial tablet and one year of stability data for NDA approval; stability studies and CMC validation are scheduled for completion by end of 2025.

• Pharmacokinetic studies are being designed to address FDA questions on absorption and safety.

• The drug has previously received an FDA approval letter, indicating substantial de-risking.

• ADPKD program may require only a single small registration trial for approval.

Market opportunity and commercialization

• Estimated addressable market for allopurinol-intolerant gout patients is $0.5–1.0B in the U.S. and CAD 700 million annually, with a projected annual drug price per patient of $6,000–8,000.

• XRx-026 targets peak sales of $2B in the U.S. for gout, while the ADPKD market opportunity is estimated at $1–6B per year.

• Commercialization strategy starts in the U.S., expanding globally, with manufacturing and distribution contracts in preparation.

• Patent portfolio covers U.S. and Europe, with protection extending to 2041-2043.

• Strategic milestones include potential licensing deals and accelerated approval pathways.